Please assess the completion status of the following clinical trial:

Trial Title: Orlistat for the Treatment of Type I Hyperlipoproteinemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Type I hyperlipoproteinemia~2. Fasting serum triglyceride levels of greater than 1000 mg/dL~3. Age \> 8 years~Exclusion Criteria:~1. Secondary hypertriglyceridemias due to diabetes, renal disease, hypothyroidism, alcoholism and drug therapy such as estrogens and estrogen analogues, steroids, HIVprotease inhibitors, retinoic acid derivatives and interferons~2. Pregnant or lactating women~3. Significant liver disease (elevated transaminases \> 2 times upper limit of normal) Alcohol abuse (\> 7 drinks or 84 g per week for women and \> 14 drinks or 168 g per week for men)~4. Severe anemia (hematocrit \< 24%)~5. Drug use (cocaine, marijuana, LSD, etc.)~6. Major surgery in the past three months~7. Congestive heart failure~8. Serum creatinine greater than 2.5 mg/dL~9. Cancer within the past five years~10. Gastrointestinal surgery in the past~11. Current therapy with anti-coagulants, digoxin, and anti-arrhythmics~12. Current therapy with cyclosporine~13. Chronic malabsorption syndromes~14. Cholestasis~15. Acute illnesses such as acute pancreatitis in the last 8 weeks

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Orlistat (Type: EXPERIMENTAL): 120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.
- Off drug (Type: NO_INTERVENTION): Standard therapy will be given for three months

Based on this trial design, predict the completion outcome and termination type (if applicable).